# Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease

Study · id `cardio:ct-nct04277702` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04277702](<https://clinicaltrials.gov/study/NCT04277702>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04277702

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04277702. Randomized; quadruple masking; primary purpose treatment. Start 2020-05 (anticipated); primary completion 2023-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04277702, source copy `cardio:ctgov-nct04277702-2020-02-20`, retrieved 2026-10-31)
- Planned start: 2020-05 (anticipated) (ClinicalTrials.gov record NCT04277702, source copy `cardio:ctgov-nct04277702-2020-02-20`, retrieved 2026-10-31)
- Primary completion: 2023-10 (anticipated) (ClinicalTrials.gov record NCT04277702, source copy `cardio:ctgov-nct04277702-2020-02-20`, retrieved 2026-10-31)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04277702, source copy `cardio:ctgov-nct04277702-2020-02-20`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04277702-2020-02-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease
- Acronym: CADET-PAD
- Condition: Peripheral Arterial Disease
- Condition: Peripheral Vascular Diseases
- Condition: Lower Limb Ischemia
- Condition: Atherosclerosis of Artery
- Intervention (Drug): Montelukast 10mg
- Intervention (Procedure): Endovascular treatment
- Intervention (Drug): Standard anti-platelet treatment
- Lead sponsor: Jagiellonian University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Jagiellonian University (`cardio:org-jagiellonian-university`)

## Provenance

Content hash: e327cb7e72b061c3ed9bdaef3c5cbca5a26ef396a1586805ff49b7def6629931
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
